CytomX Therapeutics (CTMX) Depreciation and Depletion (2016 - 2017)

CytomX Therapeutics (CTMX) posted Depreciation and Depletion of $400000.0 for Q4 2017, up 8.7% on a QoQ basis from $368000.0 in Q3 2017, and down 20.0% year-over-year from $500000.0 in Q4 2016.

CytomX Therapeutics (CTMX) Depreciation and Depletion (2016 - 2017) Analysis & Trends

CytomX Therapeutics' Depreciation and Depletion history runs 2 years deep, the most recent figure standing at $400000.0 for Q4 2017.

  • Quarterly Depreciation and Depletion fell 20.0% year-over-year to $400000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 million, down 25.0% from the prior year.
  • Depreciation and Depletion was $400000.0 for Q4 2017 at CytomX Therapeutics, up from $368000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $500000.0 in Q4 2016 and bottomed at $368000.0 in Q3 2017.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - 196,658.72
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 39.39 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 2.20 Mn
10 CytomX Therapeutics 574.36 Mn 227.66 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2017 400,000.00
Dec 31, 2017 400,000.00
Sep 30, 2017 368,000.00
Sep 30, 2017 368,000.00
Dec 31, 2016 500,000.00
Dec 31, 2016 500,000.00
Sep 30, 2016 443,000.00
Sep 30, 2016 443,000.00